Naureen Quibria

Stock Analyst at Capital One

(n/a)

# 4,602

Out of 4,970 analysts

9

Total ratings

11.11%

Success rate

-44.7%

Average return

Main Sectors:

Top Industries:

Stocks Rated by Naureen Quibria

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	BMEA Biomea Fusion	Initiates: Overweight	$25	$1.92	+1,202.08%	1	Aug 29, 2024
	IMMP Immutep	Initiates: Overweight	$10	$1.63	+513.50%	1	May 17, 2024
	ERAS Erasca	Initiates: Overweight	$8	$1.43	+459.44%	1	Mar 11, 2024
	CARM Carisma Therapeutics	Initiates: Overweight	$10	$0.37	+2,603.43%	1	Oct 3, 2023
	IMCR Immunocore Holdings	Initiates: Overweight	$84	$35.27	+138.16%	1	Aug 16, 2023
	DAWN Day One Biopharmaceuticals	Initiates: Overweight	$40	$7.48	+434.76%	1	Feb 8, 2023
	FENC Fennec Pharmaceuticals	Initiates: Overweight	$11	$8.85	+24.29%	1	Sep 7, 2022
	GNTA Genenta Science	Initiates: Buy	$21	$3.57	+488.24%	1	Jan 13, 2022
	KZIA Kazia Therapeutics	Initiates: Buy	$900	$7.89	+11,306.84%	1	Oct 14, 2021

Biomea Fusion

Aug 29, 2024

Initiates: Overweight

Price Target: $25

Current: $1.92

Upside: +1,202.08%

Immutep

May 17, 2024

Initiates: Overweight

Price Target: $10

Current: $1.63

Upside: +513.50%

Erasca

Mar 11, 2024

Initiates: Overweight

Price Target: $8

Current: $1.43

Upside: +459.44%

Carisma Therapeutics

Oct 3, 2023

Initiates: Overweight

Price Target: $10

Current: $0.37

Upside: +2,603.43%

Immunocore Holdings

Aug 16, 2023

Initiates: Overweight

Price Target: $84

Current: $35.27

Upside: +138.16%

Day One Biopharmaceuticals

Feb 8, 2023

Initiates: Overweight

Price Target: $40

Current: $7.48

Upside: +434.76%

Fennec Pharmaceuticals

Sep 7, 2022

Initiates: Overweight

Price Target: $11

Current: $8.85

Upside: +24.29%

Genenta Science

Jan 13, 2022

Initiates: Buy

Price Target: $21

Current: $3.57

Upside: +488.24%

Kazia Therapeutics

Oct 14, 2021

Initiates: Buy

Price Target: $900

Current: $7.89

Upside: +11,306.84%